1. Molecular epidemiology and clinical risk factors for rifaximin-non-susceptible Clostridioides difficile infection in South Korea: a prospective, multicentre, observational study
- Author
-
Dokyun Kim, Heejung Kim, Young Ah Kim, Yoon Park, Seok Hoon Jeong, and Jung Lim Kim
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,genetic structures ,Epidemiology ,Immunology ,Microbial Sensitivity Tests ,Microbiology ,Rifaximin ,chemistry.chemical_compound ,Risk Factors ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,Prospective Studies ,Pathogen ,Molecular Epidemiology ,Molecular epidemiology ,business.industry ,Clostridioides difficile ,Medical record ,Ribotype ,Antimicrobial ,QR1-502 ,chemistry ,Clostridium Infections ,Observational study ,CDI ,business ,Clinical risk factor - Abstract
Introduction This study was designed to investigate the molecular epidemiology of Clostridioides difficile in South Korea, and to evaluate the risk factors of rifaximin-nonsusceptible C. difficile infections (CDI). Methods A total of 413 patients with CDI from two sentinel hospitals in South Korea were enrolled in this study. Putative clinical risk factors for CDI were identified using the digital medical records of the patients, and pathogen profiles, including antimicrobial susceptibility, toxin generation, and ribotype, were evaluated for each of the causative C. difficile isolates. Results A total of 81 (19.6%) C. difficile isolates were shown to be rifaximin-nonsusceptible with the most common ribotypes being described as 018 (56.8%, 46/81), 017 (16.0%, n = 13), and 027 (6.2%, n = 5). Rifaximin-nonsusceptible C. difficile isolates exhibited higher nonsusceptibility rates to most of the other drugs tested in this study when compared to the rifaximin-susceptible isolates. Previous history of pulmonary tuberculosis and prior rifaximin treatment were shown to be linked with the occurrence of rifaximin-nonsusceptible CDIs than those with susceptible CDIs. Conclusions The rifaximin-nonsusceptibility rates for the C. difficile isolates identified in this study were reasonably high with most of these resistant strains belonging to either the 018 or 017 RT. The widespread dissemination of these clones may be the result of the antimicrobial selection pressure introduced by the widespread use of rifaximin. These results suggest that a sustainable surveillance program for C. difficile infections and resistance is needed in order to better control CDIs and improve therapeutic efficacy.
- Published
- 2021